Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization

Reuters

08/28

Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization

Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2562470435"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562470435\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562470435?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562470435","market":"fut","top_or_hot":-1,"title":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-28 13:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL9nX8lT:1","article_id":"2562470435","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562470435","pubTimestamp":1756357637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization. Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide , with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO ystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Lytix Biopharma AS宣布2025年下半年具有里程碑意义，Ruxotemitide临床试验取得进展，并为未来商业化做好战略准备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma AS Announces Milestone-Rich Second Half of 2025 with Advancements in Ruxotemitide Clinical Trials and Strategic Preparations for Future Commercialization\n    \n\n        Lytix Biopharma AS, a clinical-stage immuno-oncology company, has announced advancements in its clinical programs, positioning the company for a milestone-rich second half of 2025. The company is making strides in the development of Ruxotemitide (formerly LTX-315), with the program reaching significant milestones. A successful End-of-Phase II FDA meeting for basal cell carcinoma has been completed through its partner Verrica, and patient treatment in the ATLAS-IT-05 trial in advanced melanoma has concluded. Additionally, enrollment is ongoing in the NeoLIPA study for early-stage melanoma, with interim results anticipated in November 2025. The results for the second quarter and first half of 2025 were presented in a webcast by CEO Øystein Rekdal and CFO Gjest Breistein, with a recording available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20250827:BIT:8248:0) on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}